UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

BMC cancer, 2011-10, Vol.11 (1), p.432-432, Article 432

2011

Volltextzugriff (PDF)

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

BMC cancer, 2012-10, Vol.12 (1), p.496-496, Article 496

2012

Volltextzugriff (PDF)

Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin’s Lymphoma Resulting in Durable Clinical Responses

Journal of clinical oncology, 2006-07, Vol.24 (19), p.3107-3112

2006

Volltextzugriff (PDF)

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma

Cancer chemotherapy and pharmacology, 2011-08, Vol.68 (2), p.539-545

2011

Volltextzugriff (PDF)

A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity

Cancer chemotherapy and pharmacology, 2011-05, Vol.67 (5), p.1145-1155

2011

Volltextzugriff (PDF)

CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study

Journal of clinical oncology, 2024-08, Vol.42 (23_suppl), p.92-92

2024

Volltextzugriff (PDF)

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e16150-e16150

2024

Volltextzugriff (PDF)

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in patients with advanced neuroendocrine tumors (NETs)—A phase IIa study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16235-e16235

2023

Volltextzugriff (PDF)

BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.654-654

2024

Volltextzugriff (PDF)

Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2580-2580

2017

Volltextzugriff (PDF)

Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.LB-B25-LB-B25

2018

Volltextzugriff (PDF)

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLe a , in patients with pancreatic cancer and other CA19-9 positive malignancies

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4110-4110

2017

Volltextzugriff (PDF)

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Blood, 2012-11, Vol.120 (21), p.3615-3615

2012

Volltextzugriff (PDF)

Abstract B278: PR610: A novel hypoxia-selective tyrosine kinase inhibitor in phase I clinical trial

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.B278-B278

2013

Volltextzugriff (PDF)

Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7074-7074

2013

Volltextzugriff (PDF)

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Blood, 2011-11, Vol.118 (21), p.1523-1523

2011

Volltextzugriff (PDF)

Phase I evaluation and pharmacokinetics of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)

Cancer research (Chicago, Ill.), 1985-06, Vol.45 (6), p.2859-2865

1985

Volltextzugriff (PDF)

Phase I clinical trial of carbetimer

Cancer research (Chicago, Ill.), 1988-09, Vol.48 (18), p.5353-5357

1988

Volltextzugriff (PDF)

The impact of phase I clinical trials on the quality of life of patients with cancer

Anti-cancer drugs, 1992-12, Vol.3 (6), p.571-576

1992

Volltextzugriff (PDF)

Interferon-α therapy of renal cancer

Cancer research (Chicago, Ill.), 1984-09, Vol.44 (9), p.4140-4143

1984

Volltextzugriff (PDF)

Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics

Cancer chemotherapy and pharmacology, 1995-01, Vol.37 (1-2), p.139-149

1995

Volltextzugriff (PDF)

Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial

Journal of immunotherapy (1997), 1993-07, Vol.14 (1), p.56-64

1993

Volltextzugriff (PDF)

Phase I trials: role of the nurse investigator

Cancer treatment and research, 1989, Vol.42, p.105

Melink, T J

1989

Volltextzugriff (PDF)

Planning and implementing clinical trials

Seminars in oncology nursing, 1991-11, Vol.7 (4), p.243-251

1991

Volltextzugriff (PDF)

Phase I Trial and Biochemical Evaluation of Tiazofurin Administered on a Weekly Schedule

Selective Cancer Therapeutics, 1990, Vol.6 (1), p.51-61

1990

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Humans
(14)
Life Sciences & Biomedicine
(12)
Oncology
(12)
Science & Technology
(12)
Female
(11)
Male
(11)
Aged
(10)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Middle Aged
(10)
Adult
(9)
Antineoplastic Agents
(8)
Pharmacology. Drug Treatments
(8)
Antineoplastic Agents - Therapeutic Use
(7)
Neoplasms - Drug Therapy
(7)
Antineoplastic Agents - Adverse Effects
(5)
Chemotherapy
(5)
Pharmacology & Pharmacy
(4)
Tumors
(4)
Aged, 80 And Over
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin’s Lymphoma Resulting in Durable Clinical Responses

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma

A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity

CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in patients with advanced neuroendocrine tumors (NETs)—A phase IIa study

BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers

Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers

Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLe a , in patients with pancreatic cancer and other CA19-9 positive malignancies

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Abstract B278: PR610: A novel hypoxia-selective tyrosine kinase inhibitor in phase I clinical trial

Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Phase I evaluation and pharmacokinetics of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)

Phase I clinical trial of carbetimer

The impact of phase I clinical trials on the quality of life of patients with cancer

Interferon-α therapy of renal cancer

Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics

Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial

Phase I trials: role of the nurse investigator

Planning and implementing clinical trials

Phase I Trial and Biochemical Evaluation of Tiazofurin Administered on a Weekly Schedule

Suchergebnisse filtern